Related Experiment Video
Updated: May 10, 2026
10:17
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
Obesity, immunomodulation and chronic kidney disease
1Center for Renal Translational Medicine, Division of Nephrology-Hypertension, Department of Medicine, Institute for Metabolomic Medicine, University of California San Diego, La Jolla, CA, United States.
Current Opinion in Pharmacology
|June 12, 2013
Summary
Obesity causes inflammation and chronic kidney disease (CKD). Specialized pro-resolving mediators (SPMs) show promise in treating obesity-related kidney inflammation and damage.
Area of Science:
- Immunology
- Nephrology
- Metabolic diseases
Background:
- Obesity-induced inflammation is a significant risk factor for chronic kidney disease (CKD).
- Current CKD therapies have limited efficacy, highlighting the need for novel strategies.
- Immunomodulation is emerging as a potential therapeutic avenue for obesity-related pathologies.
Purpose of the Study:
- To review the evidence for immunomodulation as a strategy to combat obesity-related CKD.
- To explore the role of specialized pro-resolving mediators (SPMs) in mitigating obesity-induced inflammation and kidney damage.
Main Methods:
- Literature review of studies investigating SPMs in adipose tissue inflammation and kidney protection.
- Analysis of research on SPMs' effects on insulin sensitivity, adiponectin production, and leukocyte infiltration.
- Examination of the direct renoprotective effects of SPMs.
Main Results:
- SPMs, including lipoxins (LXs), resolvins, and protectins, reduce adipose inflammation.
- SPMs restore insulin sensitivity and adiponectin production in adipose tissue.
- SPMs demonstrate direct renoprotective effects and modulate leukocyte infiltration.
Conclusions:
- Immunomodulation via SPMs represents a promising therapeutic strategy for obesity-related CKD.
- Targeting inflammatory pathways with SPMs could offer a novel approach to managing CKD progression in obese individuals.
Related Concept Videos
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
01:25Chronic Kidney Disease I: Introduction
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...